ALNYLAM PHARMACEUTICALS, INC. (ALNY) vs BIOGEN INC. (BIIB)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | ALNY | BIIB |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $3.71B | $9.89B |
| Revenue growth (YoY) | ▲ 65.2% | ▲ 2.2% |
| Net income | $313.75M | $1.29B |
| Gross margin | 81.8% | 75.7% |
| Diluted EPS | $2.33 | $8.79 |
| Insider net (6 mo) | +15.8K sh • 2 sells • 0 buys | +15.7K sh • 2 sells • 0 buys |
| Institutional owners | 46 | 42 |
| Institutional value held | $29.35B | $23.28B |
| Next earnings (est.) | Around Oct 29, 2026 | Around Oct 29, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company that develops novel therapeutics based on RNA interference (RNAi), a naturally occurring biological pathway used to silence disease-causing genes by targeting messenger RNA before… Read more →
About BIOGEN INC. (BIIB)
Biogen is a global biopharmaceutical company dedicated to discovering, developing, and delivering therapies for serious and complex diseases, with a core focus on neurology, specialized immunology, and rare diseases. Read more →
Source: SEC EDGAR.